Memorial Sloan Kettering Cancer Center Gives Results of Sarcoma Drug

Memorial Sloan Kettering Cancer Center (MSKCC) Image: mskcc.org
Memorial Sloan Kettering Cancer Center (MSKCC)
Image: mskcc.org

 

A graduate of New York University’s School of Law, Steve Kanzer works as chairman and chief executive officer of Accredited Ventures, Inc. located in New York City. A philanthropic individual, Steve Kanzer supports several local endeavors, including the Memorial Sloan Kettering Cancer Center (MSKCC).

Founded in 1884, the MSKCC is the world’s oldest and largest private cancer center. Since then, the New York City center is one of 45 National Cancer Institute-designated comprehensive cancer centers. For the past 25 years, U.S. News and World Report has named the center among one of the top two national hospitals for cancer care. As of 2016, the center has 471 inpatient beds and a 72,000-square-foot surgical center.

In June 2016, MSKCC announced the results of a study pertaining to a new drug given to those with advanced soft tissue sarcoma. The multicenter phase II trial evaluated the safety and efficacy of Olaratumab in conjunction with doxorubicin chemotherapy. According to William Tap, MD, who serves as the chief of the sarcoma medical oncology service at MSKCC and corresponding author of the study, the drug extended the patients’ lives by almost one year. Based on these results, the Federal Drug Administration (FDA) has granted the drug breakthrough therapy status, which means the FDA will expedite the development of the drug.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s